Novartis RMS Webinars 2025

Myth or not?
Uncover the facts about this therapy for patients with RMS,
from its long-term efficacy data, including NEDA-3, to its proven safety and tolerability profile.

This event is provided by Novartis Pharmaceuticals Corporation.
This material was developed and approved exclusively for a US audience.

The information presented in this webinar is provided for educational purposes only and does not constitute medical advice. The content has been developed by Novartis and may not reflect the views, policies, or positions of the International Organization of MS Nurses (IOMSN). The IOMSN does not endorse any specific treatment, medication, or healthcare provider. Individuals should consult their healthcare professional to determine the best treatment options for their specific medical needs.